Ancilia Biosciences develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications.
The company is developing a proprietary platform that leverages the natural function of CRISPR to produce a new class of live biotherapeutics (LBPs) with engineered immunity to viral phages. These viral phages, or bacteriophages, comprise approximately half of the gut microbiome. Ancilia says that there is evidence that they contribute to disease and potentially limit the efficacy of LBPs.
The Ancilia platform is being developed as an essential enabling technology that identifies potentially problematic viruses in the gut using a proprietary approach to viral characterization. It then leverages the natural immune function of CRISPR to produce a new class of live biotherapeutics with immunity to these viruses.
Ancilia’s scientists have demonstrated proof of principle and filed key patents for the technology. The company’s founders and advisers include scientific leaders across CRISPR and the virome, including CSO Rodolphe Barrangou, PhD, a CRISPR pioneer who is a co-founder of Intellia Therapeutics and a former chairman of Caribou Biosciences.
Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 …
Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and …
Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases. The company engages in the discovery and development of novel therapies that …
Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by …
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …
Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation …
